Carnitine transporter CT2 (SLC22A16) is over-expressed in acute myeloid leukemia (AML) and target knockdown reduces growth and viability of AML cells

We examined the expression of the known plasma membrane carnitine transporters, OCTN1, OCTN2, and CT2 in AML cell lines and primary AML samples and compared expression to normal hematopoietic cells. Of the three carnitine transporters, CT2 demonstrated the greatest differential expression between AML and normal cells. Using shRNA, we knocked down CT2 and demonstrated that target knockdown impaired the function of the transporter. In addition, knockdown of CT2 reduced the growth and viability of AML cells with high expression of CT2 (OCI-AML2 and HL60), but not low expression. CT2 knockdown reduced basal oxygen consumption without a concomitant increase in glycolysis. Thus, CT2 may be a novel target for a subset of AML.
Source: Apoptosis - Category: Molecular Biology Source Type: research

Related Links:

Conditions:   Acute Myeloid Leukemia, in Relapse;   Myelodysplastic Syndromes Intervention:   Drug: CB-5339 Sponsor:   Cleave Therapeutics, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Publication date: Available online 26 May 2020Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Prajwal Dhakal, Elizabeth Lyden, E Muir Kate-Lynn, Zaid S. Al-Kadhimi, Lori J. Maness, Krishna Gundabolu, Vijaya Raj Bhatt
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Secondary acute myeloid leukemia (sAML) is a high-risk AML evolving from heterogenous prior hematological disorders. Compared to de novo AML, sAML has even worse responses to current therapy and thus is associated with lower remission rates, inferior overall survival (OS) and higher relapse rates. Many efforts have been devoted to improving the overall but with limited success, and novel strategy is thus highly needed. Recent research has identified that CLL1 is highly expressed on AML leukemia stem cells and blasts cells but not on normal hematopoietic stem cells. In this case report, we treated a secondary AML patient wi...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
DiscussionAs part of the HARMONY Alliance, the pilot Delphi aims to define a core outcome set in AML on the basis of a multi-stakeholder consensus. Such a core outcome set will help to allow consistent comparison of future clinical trials and real-world evidence research and ensures that appropriate outcomes valued by a range of stakeholders are measured within future trials.
Source: Trials - Category: Research Source Type: clinical trials
ConclusionThe introduction of a protocol promoting restrictive use of EAT resulted in reduction of carbapenem and vancomycin use and appears to be safe in AML or high-risk MDS patients with febrile neutropenia during chemotherapy or SCT.
Source: Antimicrobial Resistance and Infection Control - Category: Infectious Diseases Source Type: research
Acute myeloid leukemia (AML) represents a malignant disorder of the hematopoietic system that is mainly characterized by rapid proliferation, dysregulated apoptosis, and impaired differentiation of leukemic blasts. For several decades, the diagnostic approach in AML was largely based on histologic characteristics with little impact on the treatment decision-making process. This perspective has drastically changed within the past years due to the advent of novel molecular technologies, such as whole genome next-generation sequencing (NGS), and the resulting knowledge gain in AML biology and pathogenesis. After more than fou...
Source: Frontiers in Genetics - Category: Genetics & Stem Cells Source Type: research
ACS Applied Materials&InterfacesDOI: 10.1021/acsami.0c06186
Source: ACS Applied Materials and Interfaces - Category: Materials Science Authors: Source Type: research
Acute myeloid leukemia (AML) is a common hematopoietic malignancy that has a high relapse rate, and the number of regulatory T cells (Tregs) in AML patients is significantly increased. The aim of this study wa...
Source: BMC Cancer - Category: Cancer & Oncology Authors: Tags: Research article Source Type: research
Source: International Journal of Infectious Diseases - Category: Infectious Diseases Authors: Tags: Case Report Source Type: research
Contributors : Anuhar Chaturvedi ; Razif Gabdoulline ; Michael HeuserSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensMutations in the enzymes IDH1 and IDH2 have been identified in a wide variety of tumors like glioma, chondrosarcoma, thyroid cancer, lymphoma, melanoma, and in acute myeloid leukemia. Mutated IDH1/2 produces the metabolite 2-hydroxyglutarate (2HG), which interferes with epigenetic regulation of gene expression, and thus may promote tumorigenesis. Data for IDH1 inhibitors show that 30-40% of AML patients respond to monotherapy with a median duration of response of 8 mont...
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Homo sapiens Source Type: research
More News: Acute Leukemia | Acute Myeloid Leukemia | Cancer & Oncology | Leukemia | Molecular Biology | Study